Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.

摘要: Between July 1, 1981 and November 1982, 45 patients with acute nonlymphocytic leukemia (age, greater than or equal to 70 years) were randomly assigned receive induction chemotherapy using either daunorubicin, cytosine arabinoside, 6-thioguanine in full dosage (F DAT) an attenuated schedule of the same drugs (At as part Eastern Cooperative Oncology Group controlled trial. Forty deemed evaluable, 20 on each arm. The overall complete remission (CR) rate for all both arms was 28% (11/40). There no significant difference CR rates between two arms. 12 early deaths (less 60 days) F DAT arm compared only five At (P = .05). Due primarily this death rate, median survival group 29 days v 159 groups .02). range given one cycles therapy 121 414 days, while 121-186 + days. those not achieving 14 80 less Fifty-nine percent spent 100 out hospital 12% group. Attenuated lower doses is preferred regimen elderly since it causes fewer deaths, allows a better quality life, yields times durable intensive therapy.